Kid EDV by ImmunityBio for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Kid EDV overview

Kid EDV is under development for the treatment of recurrent or refractory solid or CNS tumors including diffuse intrinsic pontine gliomas of children. It is administered intravenously. The therapeutic candidate constitutes bacterially-derived nanocells loaded with mitoxantrone coated in bispecific antibodies that recognize oncogenic receptors on the tumor cell surface. The therapeutic candidate acts by targeting EGFR expressing cancer cells. It is developed based on EDV nanocell technology. It was also under development for treatment of neuroblastoma.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

For a complete picture of Kid EDV’s drug-specific PTSR and LoA scores, buy the report here.